These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32949229)

  • 81. Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels.
    Ibanez L; Dube U; Saef B; Budde J; Black K; Medvedeva A; Del-Aguila JL; Davis AA; Perlmutter JS; Harari O; Benitez BA; Cruchaga C
    BMC Neurol; 2017 Nov; 17(1):198. PubMed ID: 29141588
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study.
    Li QY; Hu HY; Zhang GW; Hu H; Ou YN; Huang LY; Wang AY; Gao PY; Ma LY; Tan L; Yu JT
    Alzheimers Res Ther; 2024 Feb; 16(1):28. PubMed ID: 38321520
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
    Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
    Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes.
    Mukaetova-Ladinska EB; Milne J; Andras A; Abdel-All Z; Cerejeira J; Greally E; Robson J; Jaros E; Perry R; McKeith IG; Brayne C; Xuereb J; Cleghorn A; Doherty J; McIntosh G; Milton I
    Dement Geriatr Cogn Disord; 2008; 26(1):32-42. PubMed ID: 18577885
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
    Nabizadeh F; Pirahesh K; Ramezannezhad E
    Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Associations of Sleep Characteristics with Cerebrospinal Fluid sTREM2 in Cognitively Normal Older Adults: the CABLE Study.
    Hu HY; Ma LZ; Hu H; Bi YL; Ma YH; Shen XN; Ou YN; Dong Q; Tan L; Yu JT
    Neurotox Res; 2021 Aug; 39(4):1372-1380. PubMed ID: 34097185
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults.
    Kresge HA; Liu D; Gupta DK; Moore EE; Osborn KE; Acosta LMY; Bell SP; Pechman KR; Gifford KA; Mendes LA; Wang TJ; Blennow K; Zetterberg H; Hohman TJ; Jefferson AL
    J Alzheimers Dis; 2020; 74(3):965-974. PubMed ID: 32144980
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
    Delgado-Alvarado M; Dacosta-Aguayo R; Navalpotro-Gómez I; Gago B; Gorostidi A; Jiménez-Urbieta H; Quiroga-Varela A; Ruiz-Martínez J; Bergareche A; Rodríguez-Oroz MC
    Mov Disord; 2018 Nov; 33(11):1809-1813. PubMed ID: 30423201
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.
    Llorens F; Kruse N; Schmitz M; Shafiq M; da Cunha JE; Gotzman N; Zafar S; Thune K; de Oliveira JR; Mollenhauer B; Zerr I
    J Neurol; 2015 Oct; 262(10):2305-11. PubMed ID: 26162713
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Altered CSF orexin and α-synuclein levels in dementia patients.
    Wennström M; Londos E; Minthon L; Nielsen HM
    J Alzheimers Dis; 2012; 29(1):125-32. PubMed ID: 22207004
    [TBL] [Abstract][Full Text] [Related]  

  • 94. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
    Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y
    PLoS One; 2016; 11(10):e0164762. PubMed ID: 27764160
    [TBL] [Abstract][Full Text] [Related]  

  • 95. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
    Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
    Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
    [TBL] [Abstract][Full Text] [Related]  

  • 97. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.
    Almeida RP; Schultz SA; Austin BP; Boots EA; Dowling NM; Gleason CE; Bendlin BB; Sager MA; Hermann BP; Zetterberg H; Carlsson CM; Johnson SC; Asthana S; Okonkwo OC
    JAMA Neurol; 2015 Jun; 72(6):699-706. PubMed ID: 25893879
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer's pathology.
    Hu H; Tan L; Bi YL; Xu W; Tan L; Shen XN; Hou XH; Ma YH; Dong Q; Yu JT
    Ann Clin Transl Neurol; 2020 Oct; 7(10):1766-1778. PubMed ID: 32910550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.